| Antibody validation J Bordeaux, AW Welsh, S Agarwal, E Killiam, MT Baquero, JA Hanna, ... Biotechniques 48 (3), 197-209, 2010 | 792 | 2010 |
| In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis V Neumeister, S Agarwal, J Bordeaux, RL Camp, DL Rimm The American journal of pathology 176 (5), 2131-2138, 2010 | 179 | 2010 |
| Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO-1 predicts improved outcomes of anti–PD-1 therapies in metastatic melanoma DB Johnson, J Bordeaux, JY Kim, C Vaupel, DL Rimm, TH Ho, ... Clinical Cancer Research 24 (21), 5250-5260, 2018 | 157 | 2018 |
| Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement DB Johnson, MJ Nixon, Y Wang, DY Wang, E Castellanos, MV Estrada, ... JCI insight 3 (24), 2018 | 151 | 2018 |
| CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell H Bitter, JM Bordeaux, B Brannetti, J Brogdon, NK Dakappagari, S Gill, ... US Patent 10,253,086, 2019 | 140 | 2019 |
| Lin28 regulates HER2 and promotes malignancy through multiple mechanisms C Feng, V Neumeister, W Ma, J Xu, L Lu, J Bordeaux, NJ Maihle, ... Cell cycle 11 (13), 2486-2494, 2012 | 91 | 2012 |
| Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling PJ Siska, RAN Johnpulle, A Zhou, J Bordeaux, JY Kim, B Dabbas, ... Oncoimmunology 6 (4), e1305535, 2017 | 81 | 2017 |
| Improved prognosis and increased tumor-infiltrating lymphocytes in patients who have SCLC with neurologic paraneoplastic syndromes WT Iams, E Shiuan, CB Meador, M Roth, J Bordeaux, C Vaupel, KL Boyd, ... Journal of Thoracic Oncology 14 (11), 1970-1981, 2019 | 71 | 2019 |
| Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen JM Bordeaux, H Cheng, AW Welsh, BG Haffty, DR Lannin, X Wu, N Su, ... PloS one 7 (5), e36559, 2012 | 66 | 2012 |
| Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma KE Beckermann, PC Jolly, JY Kim, J Bordeaux, I Puzanov, WK Rathmell, ... Journal for immunotherapy of cancer 5, 1-5, 2017 | 45 | 2017 |
| Influence of tumor microenvironment on prognosis in colorectal cancer: tissue architecture-dependent signature of endosialin (TEM-1) and associated proteins DJ O'Shannessy, EB Somers, LK Chandrasekaran, NC Nicolaides, ... Oncotarget 5 (12), 3983, 2014 | 40 | 2014 |
| Multiplexed ion beam imaging analysis for quantitation of protein expresssion in cancer tissue sections S Rost, J Giltnane, JM Bordeaux, C Hitzman, H Koeppen, SD Liu Laboratory investigation 97 (8), 992-1003, 2017 | 39* | 2017 |
| CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell H Bitter, JM Bordeaux, B Brannetti, J Brogdon, NK Dakappagari, S Gill, ... US Patent 11,149,076, 2021 | 36 | 2021 |
| MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC DA Franklin, JT Sharick, PI Ericsson-Gonzalez, V Sanchez, PT Dean, ... JCI insight 5 (15), 2020 | 32 | 2020 |
| The function, proteolytic processing, and histopathology of Met in cancer JA Hanna, J Bordeaux, DL Rimm, S Agarwal Advances in cancer research 103, 1-23, 2009 | 31 | 2009 |
| In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients M Vassilakopoulou, T Togun, U Dafni, H Cheng, J Bordeaux, ... PLoS One 9 (6), e99131, 2014 | 30 | 2014 |
| Neoadjuvant pembrolizumab and high-dose IFNα-2b in resectable regionally advanced melanoma YG Najjar, D McCurry, H Lin, Y Lin, Y Zang, D Davar, A Karunamurthy, ... Clinical Cancer Research 27 (15), 4195-4204, 2021 | 24 | 2021 |
| Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method Y Bai, H Cheng, J Bordeaux, V Neumeister, S Kumar, DL Rimm, DF Stern PLoS one 8 (11), e79901, 2013 | 18 | 2013 |
| Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)-expressing cell H Bitter, JM Bordeaux, B Brannetti, J Brogdon, NK Dakappagari, S Gill, ... US Patent App. 17/464,528, 2022 | 14 | 2022 |
| Clinical features and multiplatform molecular analysis assist in understanding patient response to anti-PD-1/PD-L1 in renal cell carcinoma E Shiuan, A Reddy, SO Dudzinski, AR Lim, A Sugiura, R Hongo, K Young, ... Cancers 13 (6), 1475, 2021 | 12 | 2021 |
